New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, November 14, 2026

Back to the front page

Q3 Earnings Updates

Q3 updates cover Crocs, Entravision and Fiserv beats, coal and oil weakness, and Xerox’s sharp decline, testing the underlying cases for recently featured stocks.

CROX $7.5BEVC $874M
Hidden Rock Capital's Newsletter

From X

@StableBread

Fajasy on X

Reviva Pharmaceuticals $RVPH now plans to apply to relist on Nasdaq in H1 2027, and its December 18 annual meeting asks shareholders to approve a reverse split of up to 1-for-100 to get there, nine months after its last one. Nasdaq suspended $RVPH on May 14 for trading below its $1.00 minimum bid price, and the stock has traded on the OTC since. At $0.35/share, $RVPH's market cap is ~$4.6M against $17.5M of cash as of September 30, or ~26% of its ~$1.33/share of cash. In my August 20 update, I wrote that steady ATM dilution looked paused, since Reviva said it doesn't expect to use its $50M ATM (selling new shares straight into the market) while it's quoted on the OTC. $RVPH's Q3 10-Q, filed November 13, says the same, and adds that the shelf registration behind the ATM expires February 13, 2027. And a company Reviva's size (under $75M of public float) needs an exchange listing to file a new shelf. RECOVER-2, the second Phase 3 trial of Reviva's schizophrenia drug brilaroxazine, plus the approval filing will cost $50-55M, CEO Laxminarayan Bhat said on an April fireside chat, about 3x Reviva's cash. The 10-Q says Reviva has no committed external sources of capital, and the Q3 earnings release still lists partnering as "pursuing partnership opportunities." So I read the reverse split and the relisting as the end of the pause in dilution: Back on Nasdaq, Reviva could sell stock again, through a new shelf or a public offering, to cover most of the $50-55M before RECOVER-2 starts. Cash fell $2.4M in Q3, and Reviva still says the $17.5M covers outlays "into the third quarter of 2027," close to the "into July 2027" it gave in August. The U.S. patent office also granted Track One priority examination to the patent application on a new formulation of brilaroxazine, which could extend the drug's protection to 2046. Track One aims for a final decision within ~12 months, and the decision can be a rejection.
@StableBread

Fajasy on X

108.4m @ 25.2g/t indium from drill hole WD26-01 is still the best assayed result of 2026 at American West Metals’ $AWMLF West Desert zinc-indium deposit in Utah. At West Desert, $AWMLF has finished five more holes (WD26-04 to WD26-08) since my August write-up. WD26-07, the westernmost so far, hit a combined 140m of visual copper and zinc sulfides and 219m of visual molybdenite, while WD26-05 and WD26-06 hit visual zinc, molybdenite, and copper oxides. Those are geologists’ visual estimates, and the October 30 quarterly report expected assays for WD26-06 and WD26-07 within 1-2 weeks, and for WD26-08 within 4-6 weeks. I found no assays for WD26-03 in $AWMLF’s releases through November 9, even though the July 31 quarterly expected them within weeks. So the 2026 program’s assayed results are still the June and July ones. $AWMLF also hired GreenMet, a Washington advisory group led by former U.S. critical minerals official Drew Horn, to pursue U.S. government funding and offtake (the right to buy its output) for West Desert. GreenMet is $AWMLF’s second Washington advisor in 2026, after Ervin Graves Strategy Group in February, and the company still hasn’t disclosed any U.S. government funding. Meanwhile, the Defense Logistics Agency (DLA), which buys for the U.S. stockpile, cancelled its July request for 400+ tonnes of indium on September 30 without an award, since traders said the request was more than the market could supply. So the stockpile’s indium purchase is off for now, and the failed request showed how thin supply is outside China (~400 tonnes/year, by one trader’s estimate). Thin supply is still the argument for funding a U.S. source like West Desert, but no agency has funded one yet. Metallurgical samples from West Desert’s historical waste dumps, one of the two extra sources of metal I flagged in August, have been shipped for test work, with no results yet. So I still don’t attach any value to West Desert in my base case. Its value in my bull case depends on the WD26-06 and WD26-07 assays confirming what geologists logged in the core.

Investor Letters

All letters

IEH Corporation: Research Note

IEH Corporation posted Q2 revenue growth of 51% to $10.7 million and a record $56 million backlog, led by defense and medical demand.

IEHC $78M
Atrium Research - Equity Research 3 clicks

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

QURE $1.7B
Triple S Special Situations Investing 2 clicks

Big Short: Fidelity & Guaranty

F&G’s main insurer held $66.5 billion of assets against $1.38 billion of statutory capital, while private credit, reinsurance dependence…

FG $3B
Mispriced Assets 5 clicks
ELALF · long

El Al Israel Airlines Ltd.

El Al Israel Airlines, $ELAL, cut costs 20% in its 2020 COVID restructuring and was taken over by U.S. investors.

ELALF $4B
Value Investors Club

What Amazon Can't Buy

Betterware de Mexico sells locally designed home organizers through direct sellers in informal neighborhoods, generating 67% gross margins;…

BWMX $677M
Phynvesting 1 click

Matan on Stitch Fix

Stitch Fix’s rushed Freestyle pivot cannibalized its profitable Fix business, driving active clients below 3.4 million, quarterly revenue…

SFIX $359M
MBI Deep Dives 2 clicks

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 88 of 294

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.